Claims for Patent: 10,143,750

Summary for Patent: 10,143,750

Title:	Method for treating cancer
Abstract:	The present invention relates to a method for the treatment of cancer in a subject which comprises the steps of: (i) administering electroporation to a tumour in the subject; and (ii) administering a T or B-cell activating agent to the subject, wherein step (i) and (ii) may be performed in either order.
Inventor(s):	Soden; Declan (Cork, IE), Forde; Patrick (Cork, IE), O\'Brien; Morgan (Cork, IE)
Assignee:	University College Cork (Cork, IE)
Application Number:	15/309,464
Patent Claims:	1. A method for the treatment of cancer in a subject, said method comprising the steps of: (i) administering electroporation and a chemotherapeutic agent to a tumour in the subject; and (ii) administering an Inducible Cell Co-Stimulator (ICOS) agonist to the subject, wherein step (i) and (ii) may be performed in either order to treat the cancer. 2. The method according to claim 1 wherein the chemotherapeutic agent is selected from the group comprising: alkylating agents, nitrosoureas, ethyleneimines methylmelamine, alkyl sulfonates, antimetabolites, pyrimidine analogs, epipodophylotoxins, L-asparaginase, IFN.alpha., IL-2, G-CSF, GM-CSF, cisplatin, carboplatin, bleomycin, anthracenediones, hydroxyurea, N-methylhydrazine (MIH), procarbazine, mitotane (o,p'-DDD), aminoglutethimide, prednisone, dexamethasone, hydroxyprogesterone caproate, medroxyprogesterone acetate megesterol acetate, diethylstillbestrol, ethyinyl estradiol, tamoxifen, testosterone propionate and fluoxymesterone, gonadotropin-releasing horome analogs, leuprolide, and flutamide. 3. The method according to claim 2 wherein the chemotherapeutic agent is cisplatin or bleomycin. 4. The method according to claim 1 wherein step (ii) comprises administering an ICOS agonist and IL-2. 5. The method according to claim 1 in which the ICOS agonist is administered systemically to the subject. 6. The method according to claim 5 in which the ICOS agonist is administered by subcutaneous (SC), intraperitoneal (IP) or intravenous (IV) administration. 7. The method according to claim 1 in which the ICOS agonist is administered by intra-tumoural (IT) administration. 8. The method according to claim 1 wherein the electroporation and the ICOS agonist are administered by pulse administration. 9. The method according to claim 1 wherein the electroporation is administered prior to the administration of the ICOS agonist. 10. The method according to claim 9 in which the ICOS agonist is administered up to 72 hours after the electroporation. 11. The method according to claim 1 wherein the interstitial pressure of the tumour is lowered prior or simultaneously to administration of the ICOS agonist. 12. The method according to claim 11 wherein the interstitial pressure of the tumour is lowered by a vacuum, a sonic wave or administration of an enzyme. 13. The method according to claim 1 wherein the ICOS agonist is administered using a `luer lock` administration. 14. The method according to claim 1 wherein the cancer is a solid tumour. 15. The method according to claim 14 wherein the solid tumor is selected from the group comprising: gastrointestinal cancer; malignant melanoma; head and nec malignancies; squamous cell carcinoma; breast carcinoma; prostate cancer; lung cancer; glioblastoma; bladder cancer; cervical cancer; chordoma; kindy cancer; liver cancer; ovarian cancer; pancreatic cancer; sarcoma; thyroid cancer; testicular cancer; uterine cancer; urethral cancer; or vulvar cancer. 16. A kit comprising an ICOS agonist and chemotherapeutic agent for use in treating cancer.

Details for Patent 10,143,750

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-05-08